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Abstract
Background: Clinical and imaging follow-up coupled with cerebrospinal fluid (CSF) and possibly serum profiling
could provide information on disease activity and disability evolution in multiple sclerosis patients.
Case presentation: We describe the case of a relapsing-remitting MS patient whose history was characterized by
failure of several therapeutic approaches and sustained disease activity. By using a highly sensitive immunoassay
methodology, we examined protein expression of 70 inflammatory/cytotoxic molecules in two consecutive paired
CSF and serum samples, obtained respectively in 2006 and 2013. At disease diagnosis, elevated CSF protein levels
of an inflammatory pattern, including CXCL13, CXCL12, IFNγ, TNF, sTNFR1, IL8, sCD163, APRIL, BAFF, pentraxin III and
MMP2 were found compared with a group of controls. At the second lumbar puncture, sustained disease activity
was accompanied by considerable (more than 2 fold changes) increase expression of most of these inflammatory
molecules while no significant changes in serum inflammatory markers were detected in the two consecutive
serum samples.
Conclusions: Elevated CSF protein expression of pro-inflammatory mediators, possibly specifically associated to GM
demyelination, could remain stable or increase over time in patients with active multiple sclerosis. We underline the
role of fluid analysis in understanding the pathophysiology of the disease and providing information on possible
markers of disease activity and evolution.
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Background
Early identification of the specific immune-phenotype of
each multiple sclerosis (MS) patient would be particularly
important at a stage in which the most appropriate disease
modifying agents could be early provided, in order to im-
prove outcomes before the onset of irreversible tissue
damage [1]. Up to now, only a detailed clinical and im-
aging follow-up analysis has helped to either obtain early
disease diagnosis or to monitor the response to treat-
ments. Advanced biomarker studies have highlighted the
importance of serum/CSF profiling in predicting features
and evolution of the disease and, possibly, the response to
therapies. A highly inflammatory intrathecal profile is a
characteristic of both relapsing-remitting [2–4] and pro-
gressive [2, 4] MS patients. We have recently shown that
elevated and specific intrathecal pro-inflammatory pattern,
including increased CSF levels of CXCL13, TNF, IFNγ,
CXCL12, IL6, IL8 and IL10, BAFF, APRIL, LIGHT,
TWEAK, sTNFR1, sCD163, MMP2 and pentraxin III,
characterizes a subgroup of MS patients with higher levels
of grey matter (GM) damage at the time of diagnosis [4].
We here describe a high and increasing over-time in-
flammatory CSF profile associated with sustained clinical
and MRI disease activity in a MS patient.
Case presentation
A 31-year-old woman was diagnosed with relapsing-
remitting multiple sclerosis (RRMS) in December 2006 (first
lumbar puncture, LP), according to revised McDonald cri-
teria [5] after an onset with severe tactil hypoaesthesia in the
left limbs. No oligoclonal bands (OCB) or increased
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intrathecal Ig synthesis were detected in the CSF; other pos-
sible causes were excluded. Her past medical history was
unremarkable except for autoimmune thyroiditis in replace-
ment therapy since 2004. At the time of diagnosis, brain
MRI showed several T2-weighted hyperintense lesions in
supratentorial and infratentorial white matter, some of them
characterized by gadolinium (Gd)-enhancement on T1-
weighted images The patient started glatiramer acetate treat-
ment. In June and December 2008 she had two relapses
(Fig. 1a); brain and spinal MRI confirmed sustained disease
activity, characterized by new T2 weighted lesions and Gd +
T1-weighted enhancing lesions. In 2009 her neurological
examination showed only mild hyposthenia in right limb.
The Expanded Disability Status Scale (EDSS) score was 2.0
Fig. 1 (A) Patient’s history was characterized by sustained disease activity. Red arrows correspond to relapses, which caused disability
accumulation. Red pentagons correspond to disease activity at MRI follow up characterized by new T2 lesions or T1 Gd-enhancing lesions.
Lumbar puncture was performed in 2006 and 2013. GA Glatiramer acetate; IFNB1a Interferon Beta-1a; NTZ Natalizumab; PEX Plasma Exchange;
CFX cyclophosphamide; DMF Dimethyl-fumarate; ALM Alemtuzumab. (B) Brain 3 T-MRI obtained at the time of second lumbar puncture (a, d, f)
and during a subsequent follow up of 2015 (b, c, e, g). Axial 3D Fluid Attenuated Inversion Recovery (FLAIR, a, b), post contrast T1w (c), 3D
Double Inversion Recovery (d, e), spinal cord STIR (f, g) are shown. Arrows indicate new lesions
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[6]. Although switched to IFNB1-a therapy (22 mcg 3/week
and then 44 mcg 3/week), she showed sustained disease ac-
tivity with two annual relapses and new typical brain lesions.
From April to August 2013 (time of second LP) she
was treated with Natalizumab, stopped due to a re-
lapse with atypical brain MRI lesions. CSF examin-
ation, repeated for suspected brain infection, excluded
viral or opportunistic infections; neither OCB or in-
creased intrathecal Ig synthesis were detected. Non
conventional 3 T MRI analysis, with DIR sequences,
showed significant cortical/iuxtacortical lesion load
(Fig. 1b): 23 GM lesions (GM lesion volume: 2438.0
cm3), of which 6 probably intracortical, were detected.
After a new optical relapse with multiple active brain
lesions, plasma exchange therapy allowed recovery of
visual impairment.
In May 2014, after a sensitive relapse, the patient started
cyclophosphamide treatment (800mg/m2 i.v. monthly)
which she carried on until March 2015. Thereafter for 3
months she was given oral dimethyl-fumarate, without ef-
fects in reducing disease activity (Fig. 1b). At that time the
patient showed severe ataxic gait with reduced vibratory
and tactile sensation, EDSS was 4.5. A specific battery of
cognitive tests [7, 8] revealed cognitive impairment, in
particular with regards to memory and attention domains.
In June 2016 she started Alemtuzumab therapy. At the
last follow-up in December 2017, no adverse effects nor
disease activity were noticed; neurological examination
showed moderate ataxic gait and patient had resumed
most of her usual activities.
Advanced protein analysis technology (Bio-Plex System,
BioRad) was used to assess the presence and levels of 70
inflammatory/cytotoxic proteins in paired serum and CSF
samples obtained from the examined MS case at the time
of diagnosis (2006, t0) and in 2013 (t1), following the pro-
cedures previously optimized [4]. By using t test and the
non-parametric Mann-Whitney test to detect potential
significant differences (p-value < 0.05) in protein levels in
the two CSF samples collected at t0 and t1, we found that
at time of diagnosis 42 inflammatory molecules overex-
pressed (at least 2 fold change, p < 0.05) in CSF of our pa-
tient (Fig. 2) respect to a control group of 26 patients
including 12 with non-inflammatory neurological diseases
and 14 with other inflammatory neurological diseases pre-
vious examined in detail [4]. Interestingly, with the excep-
tion of TNF, BAFF and IL8 that remained unchanged, 11
out of these 42 inflammatory molecules, including
CXCL13, CXCL12, IFNγ, TNF, sTNFR1, IL8, sCD163,
APRIL, BAFF, pentraxin III and MMP2, were found sig-
nificantly increased (at least 2 fold change, p < 0.05) after
7 years (Fig. 2, Additional file 1: Table S1). On the other
hand we found at the second time point (t1) a decrease in
the levels of GM-CSF, sTNFR2, TWEAK, LIGTH, sCD30,
IFNλ1, sIL6-Rβ, IL6, IL19, IL22 and IL34 (Fig. 2).
On the contrary, no substantial changes in levels of
the same inflammatory proteins have been observed in
the two consecutive paired serum samples and when
comparing these with a pool of control sera (data not
shown).
In addition, by using ELISA procedure previously opti-
mized for the analysis of CSF protein expression of neu-
rofilament light chains (Nf-L) [4], we found significant
increase of CSF levels of Nf-L from t0 (4400 pg/ml) to t1
(6300 pg/ml).
Fig. 2 Protein analysis. Percentage of the changes in cytokines levels of the samples obtained at time of diagnosis (t0) and after 7 years of follow
up (t1) CSF. Yellow bars indicate % increased levels while green bars indicate decreased levels of the inflammatory molecules. In particular,
asterisks indicate CSF biomarkers of cortical damage
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Discussion and conclusions
In this report, we have described the concurrence of
clinical and MRI activity with the increase over time of
specific CSF inflammatory markers.
Our data supports the hypothesis that an intrathecal
inflammatory profile, including in particular CXCL13,
IFNγ, TNF, CXCL12, LIGHT, IL6 and IL10, present at
the time of diagnosis, could persist and characterize all
over the disease evolution, being not easily targeted by
different treatments administered. Together with in-
creased Nf-L CSF levels over time, characterization of
this profile could help the identification of prognostic in-
flammatory and neurodegenerative biomarkers of disease
phenotypes and evolution [3, 4]. Interestingly, high dis-
ease activity was not strongly associated to significant
disability accumulation in first years of the disease when
also no oligoclonal bands or significant intrathecal Ig
synthesis were detected, which is an immunological
property of a small proportion of patients.
Among the molecular changes observed in the CSF during
the follow-up period (Fig. 2), the increased levels of IL16,
sCD163, sTNFR1, IFNα2, IFNβ, IFNγ in the CSF suggest
that both innate and adaptive immune responses persist
intrathecally and may contribute to MS pathogenesis. It is
furthermore worth mentioning that while high CSF levels of
TNF protein persist over time, the level of the pro-
inflammatory and pro-apoptotic receptor, sTNFR1, potential
marker of M1 macrophage phenotype, significantly increase,
while the level of the anti-inflammatory and pro-survival re-
ceptor, sTNFR2, possible marker of M2 macrophage pheno-
type, decrease. Despite the limitations of a single case
analysis, these data suggest that, despite the several immuno-
modulatory treatments, a shift in the balance between pro-
and anti-inflammatory pathways may induce and/or enhance
disease evolution and severity in some MS patient; we under-
line the usefulness of CSF assessment, combined with clinical
and MRI follow-up, to identify the specific immune-
inflammatory profile involved in the disease evolution of each
MS patient.
Additional file
Additional file 1: Table S1. Values of evaluated CSF proteins in the two
consecutive samples obtained respectively in 2006 (t0) and 2013 (t1).
Double arrows indicate significant changes (p < 0.05), measured by non-
parametric Mann-Whitney test. Concentrations of the molecules are
expressed as pg/ml/mg. (DOCX 33 kb)
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